- Stocks
- Healthcare
CGEM
Cullinan Therapeutics, Inc.
CGEM
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$22.09
▼ -0.32%
P/E
-6.55
Mkt Cap
$1.4B
52-Wk Range
$5.68–$23.19
52-Week Range
$5.68 - $23.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 222.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Experienced founding team led by renowned scientist Patrick A. Baeuerle
- Diversified pipeline targeting multiple cancer pathways and mechanisms
- Focus on immuno-oncology, a high-growth area in cancer therapeutics
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Advancement of clinical-stage candidates through development milestones
Value
Deep value opportunity - significant discount to Healthcare Distribution peers
Momentum
Hot
+66.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CGEM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.81 vs -$0.80 consensus (-1.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · Jul 29, 2026
vs Industry
How CGEM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related